ENTRY       D10061                      Drug
NAME        Brodalumab (USAN);
            Brodalumab (genetical recombination) (JAN);
            Siliq (TN)
PRODUCT     SILIQ (Bausch Health US LLC)
FORMULA     C6372H9840N1712O1988S52
EXACT_MASS  143814.699
MOL_WEIGHT  143903.9676
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 3999
            ATC code: L04AC12
            Product: D10061<JP/US>
EFFICACY    Antipsoriatic, Anti-IL-17A receptor antibody
  DISEASE   Plaque psoriasis [DS:H01656]
  TYPE      Monoclonal antibody
TARGET      IL17RA (CD217) [HSA:23765] [KO:K05164]
  PATHWAY   hsa04060(23765)  Cytokine-cytokine receptor interaction
            hsa04657(23765)  IL-17 signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC12 Brodalumab
                  D10061  Brodalumab (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Brodalumab
                 D10061  Brodalumab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D10061  Brodalumab (USAN); Brodalumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D10061  Brodalumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D10061  Brodalumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interleukin receptors
                IL17RA (CD217)
                 D10061  Brodalumab (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10061
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10061
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10061
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10061
DBLINKS     CAS: 1174395-19-7
            PubChem: 135626781
///
